Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Certican

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
BACKGROUND Everolimus is a proliferation signal-inhibitor recently introduced in heart transplant recipients. To date, little is… Expand
Is this relevant?
2007
2007
BACKGROUND/METHODS This observational study reports on immunosuppression with cyclosporine (CsA) in 38 de novo heart transplant… Expand
Is this relevant?
2007
2007
Everolimus (Certican; Novartis Pharma AG, Basel, Switzerland) represents the latest generation of proliferation signal inhibitors… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
The proliferation signal inhibitor everolimus (Certican), has demonstrated efficacy with full‐dose cyclosporine (CsA) (Neoral… Expand
Is this relevant?
Review
2005
Review
2005
The calcineurin inhibitors (CNIs) have been the cornerstone of immunosuppressive therapy in recent years, though their… Expand
Is this relevant?
Review
2005
Review
2005
The proliferation signal inhibitor everolimus is efficacious for reducing the incidence of acute rejection and cardiac allograft… Expand
Is this relevant?
2005
2005
Background. Everolimus (Certican), a novel proliferation signal inhibitor, allows calcineurin inhibitor dose reduction in… Expand
Is this relevant?
2005
2005
  • A. Zuckermann
  • The Journal of heart and lung transplantation…
  • 2005
  • Corpus ID: 20672719
Innovations in immunosuppressant therapy often transfer from renal transplantation to heart transplantation. Accordingly, there… Expand
Is this relevant?
2005
2005
Immunosuppressant agents have greatly increased graft and overall survival in heart transplant patients, but some of these agents… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Background. Everolimus is a proliferation inhibitor designed to target chronic rejection, including prevention of acute rejection… Expand
Is this relevant?